- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Sanofi to focus on 12 blockbuster drug candidates, immunology pipeline
New Delhi: Sanofi said on Thursday it will focus on 12 potential blockbuster drug candidates and prioritise development in immunology, as it faces investor pressure after abandoning 2025 margin targets while boosting research and development spending.
The 12 blockbuster drugs include nine medicines and vaccines with 2 billion to 5 billion euros ($2.15-$5.38 billion) in peak sales potential, and three "pipeline-in-a-product" assets with a potential of more than 5 billion euros in peak sales, Sanofi said.
The France-based drugmaker said it expects its recently launched and future pharmaceutical assets to generate more than 10 billion euros ($10.76 billion) of annual sales by 2030.
The company's top-selling anti-inflammatory drug Dupixent, which it hopes to use in treating COPD, or "smoker's lung", is expected to deliver a low double-digit rate of compounded annual net sales growth from 2023 and 2030, it said.
"We are in a privileged position today with many very promising assets in mid- and late-stage development," Sanofi's Head of Research and Development Houman Ashrafian said in a statement.
"We believe in our capacity to improve outcomes for patients globally, while bringing innovative new medicines to market and strengthening our leadership in immunology and neuro-inflammation."
The firm reiterated its expectation to generate more than 10 billion euros of annual sales from vaccines by 2030, including its recent launch of Beyfortus, which is used to prevent a common respiratory infection in infants.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story